The FDA is expected to grant approval to a new pain medication with big potential—mainly because it's a non-opioid and is ...

Part of that involves looking at the #fundamentals, but half of the disclosure comes from looking at price action.

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

These cheap shares may be takeover targets in 2025, and as such, potentially offer shareholders the chance to earn outsized returns.

2025年1月17日，生物科技公司福泰制药（VRTX）成交额为7.51亿美元，在当日美股中排第113名，成交额较昨日增加46.51%，当日成交量为177.18万。 福泰制药（VRTX）于2025年1月17日涨1.21%，报422美元，该股过去5个交易日涨3.04%，整个1月涨4.79%，年初至今涨4.79%，过去52周跌2.54%。

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

In the digital advertising space, YouTube's direct response (DR) strength, especially with QR codes, has been well-received ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal ...